Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PM10 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PM10 | DRUG | - |
Inclusion Criteria: * Be a healthy male or female 18 to 55 years of age, inclusive. Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the trial and must have a negative serum pregnancy test at screening and upon check-in to the study faci...
PM10 is an investigational small molecule being studied in healthy adult volunteers. It is being evaluated in a Phase 1 clinical trial to determine its relative effect on hemodynamics compared with placebo. The drug is not approved and remains in clinical development.
PM10 is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker BAX. The company is conducting clinical research on this investigational small molecule in healthy volunteers.
PM10 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind study in healthy adult volunteers. The drug is investigational and has not been approved for any use.
PM10 has one completed clinical trial, registered as NCT00502346. This Phase 1 study, titled 'A Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers,' enrolled 342 participants in Canada. The trial was randomized and double-blind.
The clinical trial for PM10 references PM101 in its title, suggesting the two names may refer to the same investigational drug. The study evaluates the relative effect of PM101 I.V. versus placebo on hemodynamics in healthy adult volunteers.